Total Funding
44
3
Total FundingSeries A raised
Growth Score
-3 pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
56888
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
- Lloyd Klickstein: Chief Scientific OfficerPast Role: Versanis Bio, Chief Executive Officer
Mark Pruzanski: Chairman and Chief Executive OfficerPast Role: Tigris Pharmaceuticals, Founder and Board Member
About the Company
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled
clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.
